- Home
- UMAC vs RIGL Comparison
UMAC vs RIGL Comparison
Compare UMAC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UMAC | RIGL |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | N/A | 174 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 911.8M |
| IPO Year | 2023 | 2000 |
Fundamental Metrics
Financial Performance| Metric | UMAC | RIGL |
|---|---|---|
| Price | $19.46 | $47.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $39.00 | ★ $63.00 |
| AVG Volume (30 Days) | ★ 2.2M | 233.0K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 80.73 | ★ 1867.68 |
| EPS | 0.06 | ★ 1.32 |
| Revenue | $11,199,217.00 | ★ $294,282,000.00 |
| Revenue This Year | $403.55 | $3.89 |
| Revenue Next Year | $99.03 | $21.95 |
| P/E Ratio | $332.15 | ★ $36.98 |
| Revenue Growth | ★ 101.23 | 64.15 |
| 52 Week Low | $7.25 | $24.84 |
| 52 Week High | $34.93 | $52.24 |
Technical Indicators
Market Signals| Indicator | UMAC | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 51.02 |
| Support Level | $18.09 | $43.78 |
| Resistance Level | $20.15 | $49.50 |
| Average True Range (ATR) | 1.36 | 1.81 |
| MACD | -0.37 | -0.11 |
| Stochastic Oscillator | 13.82 | 42.61 |
Price Performance
Historical ComparisonAbout UMAC Unusual Machines Inc.
Unusual Machines Inc is engaged in manufactures and sells drone components and drones across a diversified brand portfolio through business-to-business (B2B) sales and a curated retail channel.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.